{"prompt": "['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', '5.4.1 Causality (relatedness) Assessment', 'Study site investigators will assess relatedness to vaccine or study procedures (related, possibly', 'related, unlikely related, or not related) for unsolicited AEs, SAEs and AEs of special interest.', 'Relatedness determinations of these events will inform IRB reporting and safety monitoring', '(Section 5.4.3). Solicited symptoms in Tables 8 and 9 will all be considered to be related to', 'vaccine and causality assessment will not be done for these events. The study investigators will', 'use their clinical judgement to make causality assessments and may consult the Expert Safety', 'Panel or CISA Project for assistance with causality determinations. The final causality', 'assessment decision is the responsibility of the site PI where the subject was enrolled.', '5.4.2 Reporting of Adverse Events', 'COVID-19 vaccine administration will follow site-specific vaccine campaign administration', 'guidelines in accordance with current recommendations from the US Food and Drug', 'Administration and the Advisory Committee on Immunization Practices (ACIP). There are no', 'previously published COVID-19 trials evaluating the concomitant administration of influenza', 'vaccine; however, we do not foresee having a significant issue with serious adverse events', '(SAEs).', 'SAEs and unanticipated problems will be reported to the CDC and all participating IRBs', 'according to institutional requirements.', 'Adverse events that occur in a recipient following COVID-19 vaccination should be reported to', \"CDC's Vaccine Adverse Event Reporting System (VAERS). Vaccination providers are required\", 'by the Food and Drug Administration to report the following that occur after COVID-19', 'vaccination under Emergency Use Authorization:', 'Vaccine administration errors', 'Serious adverse events', 'Cases of Multisystem Inflammatory Syndrome', 'Cases of COVID-19 that result in hospitalization or death', 'Reporting is encouraged for any other clinically significant adverse event even if it is uncertain', 'whether the vaccine caused the event. Information on how to submit a report to VAERS is', 'available at https://vaers.hhs.gov external icon or by calling 1-800-822-7967.', '5.4.3 Safety Monitoring Plan', 'As a lead site, Duke will coordinate an interim safety review. This review will be performed by a', 'panel of vaccine safety experts. Duke will provide one subject matter expert to serve on the', 'safety panel. CDC will appoint two subject matter experts from other CISA sites that are not', 'participating in this study. The safety experts will review SAEs and AESI and create an interim', 'report. This review will occur once approximately 100 subjects are enrolled or at the end of the', 'influenza season, whichever occurs first. As the Lead Site, Duke will prepare narratives of the', 'SAEs and AESI for the safety panel. This plan is designed to monitor safety while minimizing', 'introduction of bias into the study and minimizing burden to study investigators.', '5.5 Health-Related Quality of Life (HRQOL)', '5.5.1 Generic Measures of HRQOL', 'HRQOL assessments will be performed at baseline and daily for 7 days following receipt of', 'either COVID-19 vaccine plus placebo or following COVID-19 vaccine plus influenza vaccine.', 'Assessments will include the EQ-5D-5L and the EQ-VAS.', '43']['Simultaneous mRNA COVID-19 and IIV4 Vaccination Study', 'Version 2.0', 'September 17, 2021', 'EQ-5D-5L', 'The EQ-5D is a standardized, generic measure of health status that provides information on', 'HRQOL and activities of daily living: mobility, self-care, usual activities, pain/discomfort and', 'anxiety/depression (http://www.eurogol.org/) 35 In addition, the instrument contains the EQ', \"Visual Analogue Scale (EQ-VAS) which measures the respondent's self-rated health.\", 'The EQ-5D-5L is the new version of the EQ-5D that increases the levels of severity from three', 'to five to significantly increase reliability and sensitivity while maintaining feasibility and reducing', 'ceiling effects (Appendix A)', '36,37 The descriptive system comprises 5 dimensions of mobility,', 'self-care, usual activities, pain/discomfort, anxiety /depression. For each of these dimensions,', 'there are 5 response levels: no problems, slight problems, moderate problems, severe', 'problems, and extreme problems. The respondent is asked to indicate his/her health state by', 'ticking in the box against the most appropriate statement in each of the 5 dimensions. This', 'decision results in a 1-digit number expressing the level selected for that dimension. The digits', \"for 5 dimensions can be combined in a 5-digit number describing the respondent's health state\", 'from 11111 as best health and 55555 as worst health These numbers are converted to a Utility', 'Index that ranges from -0.109 (worst health) to 1.000 (best health) for US specific values. The', 'minimum clinically important difference ranges from 0.05 to 0.1 depending on health conditions', 'being studied.', 'EQ-VAS', \"The EQ-VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue\", 'scale with endpoints labelled \"the best health you can imagine\\' (100) and \"the worst health you', 'can imagine\\' (0). The respondent marks an \"X\\' on the scale number to indicate how their health', 'is \"today.\\' The minimum clinically important difference on the VAS is 8.', 'The EQ-5D-5L and EQ-VAS have several advantages for use in this study. The measure is', 'applicable to a wide range of health conditions and treatments and provide a simple descriptive', 'profile and a single index value for health status. It has been validated in US and international', 'populations and in adolescents and adults of all ages 35,38,39', 'The', 'measure', 'is', 'useful', 'for', 'monitoring the health status of patient groups at different moments in time and assessing the', 'seriousness of conditions at different moments in time. The measure is designed for self-', 'completion by respondents. It is simple, straightforward, take only a few minutes to complete', 'and can easily be completed by adolescents and older adults. The instrument was designed to', 'reduce respondent burden while achieving standards of precision for purposes of group', 'comparisons involving multiple health dimensions. It has been widely used throughout the', 'world in many different studies, including randomized controlled clinical trials, vaccine studies,', 'and HRQOL studies.', '5.6 Biospecimens Collection & Handling', '5.6.1 Serum', 'Blood specimens will be collected during study visits as described in Tables 5 and 6.', 'All blood samples (=10 mL) will be collected into serum separator tubes and processed as', 'follows:', '44']\n\n###\n\n", "completion": "END"}